By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
INTRODUCTION
Eplerenone, marketed under the trade name Inspra, is a potassium-saving diuretic that acts as an aldosterone antagonist and is used to treat chronic heart failure and high blood pressure, especially in people who have resistant hypertension brought on by increased aldosterone.
It treats heart failure and lowers the chance of developing other heart issues or a stroke. It also aids in preventing the progression of heart failure. Hyperaldosteronism is a condition that it can occasionally be used to cure. When the body produces too much aldosterone, a hormone that regulates blood pressure, this occurs.Long-term treatment with eplerenone is possible.
GLOBAL EPLERENONE MARKET SIZE AND FORECAST
The Global EPLERENONE market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
RECENT DEVELOPMENT
In response to advice from the trial’s independent Executive Steering Committee, Pfizer Inc. declared that it intends to stop recruiting participants early in the EMPHASIS-HF trial.
The recommendations come after a second interim analysis by the EMPHASIS-HF trial’s independent Data Safety Monitoring Committee, which confirmed the study’s primary effectiveness endpoint had been attained early in accordance with the protocol’s pre-defined stopping procedures.
In comparison to patients on the placebo arm of the trial, who received standard care along with a matching placebo, the interim analysis revealed that patients treated with INSPRA® (eplerenone), in addition to current standard of care, had a significantly lower risk of cardiovascular (CV) death or heart failure (HF) hospitalisation.
The trial’s placebo arm, where patients received standard care along with a matching placebo, saw a significant increase in the risk of cardiovascular (CV) death or heart failure (HF) hospitalisation, according to the interim analysis.
Patients treated with INSPRA® (eplerenone), in addition to standard care, did not experience this risk. Plerenone was generally well tolerated during the EMPHASIS-HF study, according to the interim analysis performed by the independent data safety monitoring committee.
Both hyperkalemia (elevated potassium) (8 percent in the eplerenone group vs 3% in the placebo group; p 0.001) and renal impairment (4 percent in the eplerenone group vs 2% in the placebo group; p 0.05) were listed as adverse events. Agents that act as mineralocorticoid receptor antagonists frequently cause these negative effects
. In the double-blind, placebo-controlled, parallel group EMPHASIS-HF trial, patients with mild chronic systolic heart failure (NYHA functional Class II) and left ventricular systolic dysfunction were compared between eplerenone plus standard heart failure therapy and placebo plus standard heart failure therapy.
COMPANY PROFILE
THIS REPORT WILL ANSWER FOLLOWING QUESTIONS
